Showing posts with the label Immunomedics

Gilead Sciences Completes Acquisition of Immunomedics, Inc.

Gilead Sciences today announced the completion of the previously announced transaction to acquire Immunomedics , Inc. for approximately $21 billion in the aggregate. Daniel O’Day, Chairman and Chief…

Immunomedics Announces FDA Orphan Drug Designation of TrodelvyTM for Glioblastoma

Immunomedics Inc, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan status for the…
Subscribe Our Newsletter